These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16882128)

  • 1. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results.
    Body JJ; Diel IJ; Tripathy D; Bergstrom B
    Eur J Cancer Care (Engl); 2006 Jul; 15(3):299-302. PubMed ID: 16882128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
    von Moos R; Caspar CB; Steiner R; Angst R; Inauen R; Schmieding K; Thürlimann B
    Onkologie; 2010; 33(8-9):447-50. PubMed ID: 20838060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial.
    Pivot X; Lortholary A; Abadie-Lacourtoisie S; Mefti-Lacheraf F; Pujade-Lauraine E; Lefeuvre C; Letessier S; Morvan P; Dür C; Frimat L
    Breast; 2011 Dec; 20(6):510-4. PubMed ID: 21727006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.
    Heras P; Karagiannis S; Kritikos K; Hatzopoulos A; Mitsibounas D
    Eur J Cancer Care (Engl); 2007 Nov; 16(6):539-42. PubMed ID: 17944770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.
    Pecherstorfer M; Diel IJ
    Support Care Cancer; 2004 Dec; 12(12):877-81. PubMed ID: 15372222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
    Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
    Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
    Tripathy D; Body JJ; Bergström B
    Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer.
    Heras P; Kritikos K; Hatzopoulos A; Georgopoulou AP
    Eur J Cancer Care (Engl); 2009 Nov; 18(6):653-6. PubMed ID: 19552728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal safety of ibandronate.
    Jackson GH
    Oncologist; 2005; 10 Suppl 1():14-8. PubMed ID: 16264108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
    Diel IJ; Body JJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
    Eur J Cancer; 2004 Jul; 40(11):1704-12. PubMed ID: 15251160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.
    von Moos R; Caspar CB; Thürlimann B; Angst R; Inauen R; Greil R; Bergstrom B; Schmieding K; Pecherstorfer M
    Ann Oncol; 2008 Jul; 19(7):1266-1270. PubMed ID: 18334511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of ibandronate in the daily oncological practice].
    Nagykálnai T
    Magy Onkol; 2006; 50(4):325-7. PubMed ID: 17216006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid infusion of ibandronate in lung cancer patients with bone metastases.
    Kiagia M; Karapanagiotou E; Charpidou A; Dilana K; Dionellis G; Dannos I; Georgiou E; Syrigos KN
    Anticancer Res; 2006; 26(4B):3133-6. PubMed ID: 16886646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.
    Pecherstorfer M; Rivkin S; Body JJ; Diel I; Bergström B
    Clin Drug Investig; 2006; 26(6):315-22. PubMed ID: 17163265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection.
    Pecherstorfer M; Ludwig H; Schlosser K; Buck S; Huss HJ; Body JJ
    J Bone Miner Res; 1996 May; 11(5):587-93. PubMed ID: 9157773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.
    Meattini I; Bruni A; Scotti V; Livi L; De Luca Cardillo C; Galardi A; Cipressi S; Biti G
    J Chemother; 2010 Feb; 22(1):58-62. PubMed ID: 20227995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
    Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
    Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.